Abiopharma

LIQUIDITY SERVICES INC (LQDT) Reports the reporting period Financial Results LIQUIDITY SERVICES INC (LQDT) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 10
• Net Income: 15011
• EPS: $0.23
• Cash and equivalents: 195308
  • expected in the low-to-mid eighties as a percentage of total GMV. Consolidated revenue as a percentage of GMV is expected to be in the mid-to-high twenties, and total segment direct profit as a percentage of consolidated revenue is expected to again be in the mid-to-high forty percent range. These ratios can vary based on our overall business mix, including asset categories, in any given period.Our Q3-FY26 guidance is as follows: $ in millions, except per share data Q3-FY26 Guidance GMV $425 to $465 GAAP Net Income $7.0 to $10.0 Non-GAAP Adjusted EBITDA $17.0 to $20.0 GAAP Diluted EPS $0.21 to $0.30 Non-GAAP Adjusted Diluted EPS $0.30 to $0.39 Our Business Outlook includes forward-looking statements which reflect the following trends and assumptions for Q3-FY26 as compared to the prior year's period, as well as the other risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the year ended September 30, 2025
  • targeting efficient payback periods;•variability in the volumes and sourcing locations of products handled by our RSCG segment, which can cause the capacity and related operating expense requirements for inventory logistics and storage to fluctuate; Potential Impacts to GAAP Net Income and Diluted EPS and Non-GAAP Adjusted Net Income and Adjusted Diluted EPS•our FY26 annual effective tax rate (ETR) is expected to range from approximately 30% to 34%, with a slightly higher rate in the mid thirties for the fiscal third quarter of 2026